ABUS vs O · P/E 5.4, rev $6.2M vs P/E 50, rev $5.27B
Arbutus Biopharma Corp (ABUS) versus Realty Income Corporation (O) — a side-by-side from cached financials, not a winner call.
Arbutus Biopharma Corp (ABUS) is a biotechnology company listed on NASDAQ.
Realty Income Corporation (O) is a reit - retail company listed on NYSE.
Latest reported ABUS revenue for 2024-12-31 was $6.2M. Net income was -$69.9M. Revenue was down 66.0% from 2023-12-31 to 2024-12-31. ABUS currently screens at market cap $883.0M and trailing P/E 5.4.
Latest reported O revenue for 2024-12-31 was $5.27B. Net income was $867.3M. Revenue was up 29.2% from 2023-12-31 to 2024-12-31. O currently screens at market cap $56.48B and trailing P/E 49.6.
ABUS currently screens at market cap $883.0M and trailing P/E 5.4. O currently screens at market cap $56.48B and trailing P/E 49.6.
Not investment advice. Open the ABUS and O stock pages for the full models.
Not investment advice.